RxDoctor Payments Data

Emily Schehlein, MD

Glaucoma Specialist · Brighton, MINPI 1538692421

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Alcon at 57.0% of the total.

$43,776in general payments, 2019–2025

Across 80 payments — averaging $547.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$25K
  • Glaukos Corporation$8K
  • AbbVie$6K
  • Alcon Research LLC$3K
  • Nova Eye, Inc.$2K
  • Tarsus Pharmaceuticals, Inc.$226
  • plus $359 from 6 others

What the payments were for

  • Consulting fees$20,79548%
  • Speaking & faculty fees$14,30033%
  • Travel & lodging$4,34210%
  • Food & beverage$4,34010%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$199,935
Medicare patients
450
Services billed
1,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine11$16,556
LumiganBimatoprost31$14,892
Bromfenac Sodium46$12,062
Prednisolone Acetate347$11,265
Cyclosporine23$9,933
RocklatanNetarsudil Mesylat/Latanoprost20$9,234
SimbrinzaBrinzolamide/Brimonidine Tart27$6,724
Latanoprost457$6,674
RhopressaNetarsudil Mesylate15$5,256
Brimonidine Tartrate78$4,580
Dorzolamide-TimololDorzolamide/Timolol/Pf33$3,907
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat121$2,406
Tobramycin-DexamethasoneTobramycin/Dexamethasone49$2,176
Timolol Maleate87$1,290
Dorzolamide Hcl27$923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$5,509$31,44842 claims
AlconSimbrinza$24,952$6,72427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Brighton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →